

Christoph J Stephan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8989718/publications.pdf>

Version: 2024-02-01

110
papers

3,449
citations

159358

30
h-index

155451

55
g-index

118
all docs

118
docs citations

118
times ranked

5492
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 363-371.	4.6	345
2	All-cause mortality in treated HIV-infected adults with CD4 \geq 500/mm ³ compared with the general population: evidence from a large European observational cohort collaboration. <i>International Journal of Epidemiology</i> , 2012, 41, 433-445.	0.9	217
3	Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. <i>Lancet</i> , The, 2015, 385, 1428-1435.	6.3	199
4	Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. <i>Lancet</i> , The, 2015, 385, 1098-1106.	6.3	170
5	Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, e8-e16.	0.9	142
6	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for \geq 3 Years With Incomplete CD4 Recovery. <i>Clinical Infectious Diseases</i> , 2014, 58, 1312-1321.	2.9	140
7	Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever. <i>Clinical Infectious Diseases</i> , 2017, 65, 855-859.	2.9	101
8	Is It Safe to Discontinue Primary <i>Pneumocystis jirovecii</i> Pneumonia Prophylaxis in Patients with Virologically Suppressed HIV Infection and a CD4 Cell Count \geq 200 Cells/ μ L?. <i>Clinical Infectious Diseases</i> , 2010, 51, 611-619.	2.9	96
9	Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country. <i>Aids</i> , 2008, 22, 2471-2479.	1.0	90
10	Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort. <i>Aids</i> , 2018, 32, 2405-2416.	1.0	83
11	New Lineage of Lassa Virus, Togo, 2016. <i>Emerging Infectious Diseases</i> , 2018, 24, 599-602.	2.0	79
12	CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>Clinical Infectious Diseases</i> , 2017, 65, 959-966.	2.9	75
13	Suppression of HBV by Tenofovir in HBV/HIV Coinfected Patients: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e68152.	1.1	75
14	Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. <i>Aids</i> , 2013, 27, 803-813.	1.0	70
15	Presence of <i>Chlamydia pneumoniae</i> DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis. <i>Annals of Neurology</i> , 2001, 49, 585-589.	2.8	65
16	Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2021, 223, 56-61.	1.9	65
17	Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. <i>Aids</i> , 2008, 22, 2279-2289.	1.0	64
18	Immune Response after Two Doses of the Novel Split Virion, Adjuvanted Pandemic H1N1 Influenza A Vaccine in HIV-1-Infected Patients. <i>Clinical Infectious Diseases</i> , 2011, 52, 122-127.	2.9	64

#	ARTICLE	IF	CITATIONS
19	Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. <i>Aids</i> , 2010, 24, F31-F35.	1.0	61
20	Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. <i>Clinical Infectious Diseases</i> , 2016, 62, 1571-1577.	2.9	52
21	Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study. <i>Journal of Electrocardiology</i> , 2011, 44, 779-785.	0.4	47
22	Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. <i>Aids</i> , 2004, 18, 503-508.	1.0	46
23	The Management of Needlestick Injuries. <i>Deutsches Arzteblatt International</i> , 2013, 110, 61-7.	0.6	45
24	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 1316-1326.	2.9	44
25	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. <i>International Journal of Epidemiology</i> , 2016, 45, 2038-2049.	0.9	43
26	Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 1087-1093.	1.3	40
27	Needlestick injuries: causes, preventability and psychological impact. <i>Infection</i> , 2014, 42, 549-52.	2.3	40
28	Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. <i>Lancet HIV</i> , 2021, 8, e711-e722.	2.1	35
29	Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥ 50 Years: Final 96-Week Results of the NEAT022 Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 597-606.	2.9	34
30	The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 1024-1030.	1.3	31
31	Colonization with multidrug-resistant organisms is associated with increased mortality in liver transplant candidates. <i>PLoS ONE</i> , 2021, 16, e0245091.	1.1	29
32	Antibody response to SARS-CoV-2 for more than one year: Kinetics and persistence of detection are predominantly determined by avidity progression and test design. <i>Journal of Clinical Virology</i> , 2022, 146, 105052.	1.6	29
33	Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis. <i>Scandinavian Journal of Infectious Diseases</i> , 2005, 37, 520-522.	1.5	26
34	Cryptococcosis due to <i>Cryptococcus gattii</i> in Germany from 2004-2013. <i>International Journal of Medical Microbiology</i> , 2015, 305, 719-723.	1.5	26
35	Myocardial Fibrosis and Inflammation by CMR Predict Cardiovascular Outcome in People Living With HIV. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1548-1557.	2.3	26
36	Renal AA-amyloidosis in intravenous drug users: a role for HIV-infection?. <i>BMC Nephrology</i> , 2012, 13, 151.	0.8	25

#	ARTICLE	IF	CITATIONS
37	Impact of baseline HIV RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials. <i>HIV Medicine</i> , 2013, 14, 284-292.	1.0	25
38	Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1 Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 80, 292-300.	0.9	24
39	Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 83, 240-250.	0.9	24
40	The role of <i>Enterococcus</i> spp. and multidrug-resistant bacteria causing pyogenic liver abscesses. <i>BMC Infectious Diseases</i> , 2017, 17, 450.	1.3	23
41	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw519.	2.9	20
42	Pharmacokinetics, Safety and Efficacy of Saquinavir/ Ritonavir 1,000/100 Mg Twice Daily as HIV Type-1 Therapy and Transmission Prophylaxis in Pregnancy. <i>Antiviral Therapy</i> , 2008, 13, 1039-1046.	0.6	20
43	Travel-Acquired Dengue Infection: Clinical Spectrum and Diagnostic Aspects. <i>Infection</i> , 2002, 30, 225-228.	2.3	18
44	Biomarkers and Bacterial Pneumonia Risk in Patients with Treated HIV Infection: A Case-Control Study. <i>PLoS ONE</i> , 2013, 8, e56249.	1.1	18
45	CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. <i>Clinical Infectious Diseases</i> , 2021, 73, 50-59.	2.9	18
46	Not Recommended, But Done: Breastfeeding with HIV in Germany. <i>AIDS Patient Care and STDs</i> , 2021, 35, 33-38.	1.1	17
47	Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, <i>Pneumocystis jirovecii</i> -pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study). <i>AIDS Research and Therapy</i> , 2019, 16, 34.	0.7	16
48	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2323-e2333.	2.9	16
49	Antifungal therapy in patients with pulmonary <i>Candida</i> spp. colonization may have no beneficial effects. <i>Journal of Intensive Care</i> , 2015, 3, 31.	1.3	15
50	Cytokine and Chemokine Signature in Elite Versus Viremic Controllers Infected with HIV. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 579-587.	0.5	15
51	Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial. <i>Hepatology</i> , 2019, 69, 1135-1150.	3.6	15
52	Antiviral Activity, Pharmacokinetics, and Safety of the HIV-1 Protease Inhibitor TMC310911, Coadministered With Ritonavir, in Treatment-Naive HIV-1 Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 65, 283-289.	0.9	14
53	CD4 ⁺ T cell lymphopenia predicts mortality from <i>Pneumocystis</i> pneumonia in kidney transplant patients. <i>Clinical Transplantation</i> , 2020, 34, e13877.	0.8	13
54	Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 59, 294-299.	0.9	13

#	ARTICLE	IF	CITATIONS
55	HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy. <i>Medical Microbiology and Immunology</i> , 2016, 205, 575-583.	2.6	12
56	Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254. <i>Clinical Infectious Diseases</i> , 2022, 75, 786-794.	2.9	12
57	Research Letter. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, e73-e75.	0.9	11
58	Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus H5N1 Influenza Vaccine in Chronically Ill and Immunocompromised Patients. <i>Vaccine Journal</i> , 2014, 21, 867-876.	3.2	11
59	Elevated prevalence of multidrug-resistant gram-negative organisms in HIV positive men. <i>BMC Infectious Diseases</i> , 2017, 17, 206.	1.3	11
60	Quadruple Nucleos(t)ide Reverse Transcriptase Inhibitors-Only Regimen of Tenofovir Plus Zidovudine/Lamivudine/Abacavir in Heavily Pre-Treated HIV-1 Infected Patients: Salvage Therapy or Backbone Only?. <i>Current HIV Research</i> , 2009, 7, 320-326.	0.2	10
61	Immune Response after a Single Dose of the 2010/11 Trivalent, Seasonal Influenza Vaccine in HIV-1-Infected Patients and Healthy Controls. <i>HIV Clinical Trials</i> , 2013, 14, 175-184.	2.0	10
62	Impact of raltegravir on HIV-1 RNA and DNA forms following initiation of antiretroviral therapy in treatment-naïve patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2809-2818.	1.3	10
63	Dose reduction effective in alleviating symptoms of saquinavir toxicity. <i>International Journal of STD and AIDS</i> , 2007, 18, 81-84.	0.5	9
64	Treatment modification after starting cART in people living with HIV: retrospective analysis of the German ClinSurv HIV Cohort 2005-2017. <i>Infection</i> , 2020, 48, 723-733.	2.3	9
65	Reasons for Choice of Antiretroviral Regimens in HIV Patients Presenting Late for Initial Treatment in Europe. <i>AIDS Patient Care and STDs</i> , 2021, 35, 110-115.	1.1	9
66	High overall mortality of Mycobacterium genavense infections and impact of antimycobacterial therapy: Systematic review and individual patient data meta-analysis. <i>Journal of Infection</i> , 2022, 84, 8-16.	1.7	9
67	Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 375-381.	0.8	8
68	Optimization of the EC26-2A4 Epitope in the gp41 Membrane Proximal External Region Targeted by Neutralizing Antibodies from an Elite Controller. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 365-374.	0.5	8
69	Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. <i>Clinical Infectious Diseases</i> , 2021, 73, 195-202.	2.9	8
70	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/μL. <i>Journal of the International AIDS Society</i> , 2021, 24, e25726.	1.2	8
71	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. <i>PLoS ONE</i> , 2020, 15, e0243625.	1.1	8
72	Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of resensitising mutations including K65R. <i>Journal of Infection</i> , 2010, 61, 346-350.	1.7	7

#	ARTICLE	IF	CITATIONS
73	Comparison of Drug Resistance Scores for Tipranavir in Protease Inhibitor-Na ⁺ ve Patients Infected with HIV-1 B and Non-B Subtypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5362-5366.	1.4	7
74	Predictors of CD4+ T-Cell Counts of HIV Type 1â€“Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. <i>Journal of Infectious Diseases</i> , 2013, 207, 759-767.	1.9	7
75	Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children â€“ a EuroCoord-CHAIN-EPPICC joint project. <i>BMC Infectious Diseases</i> , 2016, 16, 654.	1.3	7
76	Decrease of Atazanavir and Lopinavir Plasma Concentrations in a Boosted Double Human Immunodeficiency Virus Protease Inhibitor Salvage Regimen. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2273-2275.	1.4	6
77	Experience with tenofovir disoproxil fumarate for antiretroviral therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1197-1209.	0.9	6
78	HIV-associated lung cancer: Survival in an unselected cohort. <i>Scandinavian Journal of Infectious Diseases</i> , 2013, 45, 766-772.	1.5	6
79	Autologous stem cell transplantation in HIV-related lymphoma in the rituximab era - a feasibility study in a monocentric cohort. <i>Journal of the International AIDS Society</i> , 2014, 17, 19648.	1.2	5
80	Improved virological and immunological efficacy of resistance-guided switch in antiretroviral therapy: a Frankfurt HIV cohort analysis. <i>Medical Microbiology and Immunology</i> , 2014, 203, 409-414.	2.6	5
81	Disseminated disease due to non-tuberculous mycobacteria in HIV positive patients: A retrospective case control study. <i>PLoS ONE</i> , 2021, 16, e0254607.	1.1	5
82	Winterbottom's Sign and Hypertrophic Cardiomyopathy. <i>Scandinavian Journal of Infectious Diseases</i> , 2002, 34, 544-545.	1.5	4
83	Finding of nevirapine extended release tablet remnants in stools does not threaten the success of combination antiretroviral therapy. <i>HIV Medicine</i> , 2014, 15, 124-128.	1.0	4
84	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1352-1360.	1.3	4
85	Species distribution and clinical features of infection and colonisation with non-tuberculous mycobacteria in a tertiary care centre, central Germany, 2006â€“2016. <i>Infection</i> , 2019, 47, 817-825.	2.3	4
86	Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. <i>Aids</i> , 2021, 35, 2025-2033.	1.0	4
87	Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy. <i>Medical Microbiology and Immunology</i> , 2013, 202, 117-124.	2.6	3
88	Durability of protective antibody titres is not enhanced by a two-dose schedule of an ASO3-adjuvanted pandemic H1N1 influenza vaccine in adult HIV-1-infected patients. <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 656-659.	1.5	3
89	Prevalence of K65R in patients treated with tenofovir disoproxil fumarate: recommendations based on the Frankfurt HIV Cohort Study Resistance Database (FHCS-RD). <i>Medical Microbiology and Immunology</i> , 2016, 205, 315-320.	2.6	3
90	Ischemic stroke in human immunodeficiency virus-positive patients: An increasingly age-related comorbidity?. <i>European Stroke Journal</i> , 2020, 5, 252-261.	2.7	3

#	ARTICLE	IF	CITATIONS
91	Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 86, 248-257.	0.9	3
92	Influence of tenofovir exposure in utero on primary dentition. <i>European Journal of Pediatrics</i> , 2020, 179, 1761-1768.	1.3	3
93	Virological efficacy and safety of antiretroviral therapy-switch to atazanavir-based regimen: a review of the literature. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2355-2367.	0.9	2
94	144-week outcomes of lopinavir/ritonavir (LPV/r)-based first-line ART in 1,409 HIV-infected patients: data from the German STAR/STELLA cohort. <i>Journal of the International AIDS Society</i> , 2014, 17, 19770.	1.2	2
95	Proton 1H and Phosphorus 31P MR spectroscopy (MRS) in asymptomatic HIV-positive patients. <i>Journal of the International AIDS Society</i> , 2014, 17, 19577.	1.2	2
96	Performance of the Abbott RealTime HIV-1 assay versus the Roche Amplicor HIV-1 Monitor™ Test, v1.5, UltraSensitive assay for samples with low plasma HIV-1 RNA copy numbers. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1708-1710.	1.3	2
97	Lopinavir/Ritonavir Pharmacokinetics, Efficacy, and Safety in HIV and Hepatitis B or C Coinfected Adults Without Symptoms of Hepatic Impairment. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 192-201.	1.0	2
98	Evolution and function of the HCV NS3 protease in patients with acute hepatitis C and HIV coinfection. <i>Virology</i> , 2015, 485, 213-222.	1.1	2
99	Rapid regression of Kaposi's sarcoma of the hard palate under therapy with boosted elvitegravir-containing fixed-dose antiretroviral combination therapy. <i>Infection</i> , 2016, 44, 103-106.	2.3	2
100	Risk factors for IRIS in HIV-associated Pneumocystis-pneumonia following ART initiation. <i>Journal of Infection</i> , 2021, 83, 347-353.	1.7	2
101	Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients. <i>European Journal of Medical Research</i> , 2010, 15, 369.	0.9	1
102	Drug Resistance Spread in 6 Metropolitan Regions, Germany, 2001–2018. <i>Emerging Infectious Diseases</i> , 2020, 26, 2439-2443.	2.0	1
103	Evaluation of Platelet Activation by HIV Protease Inhibitors – The HIV-PLA II Study. <i>HIV/AIDS - Research and Palliative Care</i> , 2021, Volume 13, 789-800.	0.4	1
104	Phenotypic Diversity of <i>Cryptococcus neoformans</i> var. <i>neoformans</i> Clinical Isolates from Localized and Disseminated Infections. <i>Microorganisms</i> , 2022, 10, 321.	1.6	1
105	Haemolytic anaemia after nucleotide antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient. <i>Aids</i> , 2004, 18, 1613-1614.	1.0	0
106	Comparison of Roche Amplicor Ultrasensitive and Abbott RealTime assays for samples with low or undetectable HIV RNA levels. <i>Aids</i> , 2012, 26, 1580-1581.	1.0	0
107	Depression in HIV-positive women is associated with changes in antiretroviral treatment regimens. <i>Journal of the International AIDS Society</i> , 2014, 17, 19720.	1.2	0
108	Three Nonnucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1. <i>Annals of Internal Medicine</i> , 2015, 162, 460-461.	2.0	0

#	ARTICLE	IF	CITATIONS
109	P045...Switching from boosted atazanavir (ATV) plus FTC/TDF to a TAF-based single tablet regimen (STR): week 48 data in virologically suppressed adults. Sexually Transmitted Infections, 2016, 92, A34.1-A34.	0.8	0
110	HLA...B57.01 shields people living with HIV for significantly better periodontal health. Journal of Periodontology, 2018, 89, 966-972.	1.7	0